But a treatment gap remains
*Calculated using 2020 Hospital Pharmacy Audit data (purchased from IQVIA) and total 2020 PD prevalence data using Parkinson’s UK report (as referenced).
Prevalence of complex Parkinson’s disease applied from the 2019 Parkinson’s UK report (as referenced).
The 5-2-1 criteria could help you identify patients with PD who may be progressing into the complex/advanced stage and may be eligible for non-oral therapies. Look out for the following signs:2
5-2-1 open dialogue resource
Get support for practical and early non-oral therapy discussions with tips on how to have an open conversation with patients and their loved ones
Learn about the progression of PD
5-2-1 open dialogue resource
Get support for practical and early non-oral therapy discussions with tips on how to have an open conversation with patients and their loved ones
Discover more about the impact of sub-optimally controlled PD in your patients
Patients with PD who experience ‘OFF’ time may have diffculty performing everyday activities and communicating effectively16,19-21
In an online US survey of 2,110 patients with PD, that assessed their lived experience of ‘OFF’ periods:
Nearly a quarter of their waking hours were spent in ‘OFF’ state (mean disease duration 6.1 years), which comprised both motor and non-motor symptoms.19
Patients with PD reported a wide range of motor symptoms during their ‘OFF’ times, with some describing these symptoms as ‘constant tremors’, being ‘frozen in place’ and ‘moving in slow motion’.19
Findings from 3 studies whose aims all included exploring the impact of ‘OFF’ periods on PD patients (An online survey of 305 patients exploring the impact of ‘OFF’ time on health related quality of life and daily functioning in people with PD, a scoping review that included 23 studies that evaluated the impact or experience of ‘OFF’ periods in PD patients, and an epidemiological survey of a multicentre, observational crosssectional study of 617 patients assessing the frequency of wearing ‘OFF’ in patients with PD and its impact on quality of life.
‘OFF’ times made it impossible for them to leave the house on their own and affected their ability to communicate effectively.16,20,21
People with PD who experience troublesome dyskinesia may have difficulty with a range of daily activities14
An analysis that assessed the impact of dyskinesia on activities of daily living using pooled United Dyskinesia Rating Scale (UDysRS) data from two Phase 3 clinical trials showed that mild-to-severe impacts of dyskinesia can include impact on:
5-2-1 open dialogue resource
Get support for practical and early non-oral therapy discussions with tips on how to have an open conversation with patients and their loved ones
Discover why earlier patient assessment for non-oral therapies is important
Peer-reviewed opinions support earlier introduction of non-oral therapies in patients with complex/advanced Parkinson’s disease3
When left too late, non-oral therapies may no longer be an appropriate treatment option for patients with PD3
When initiation of non-oral therapies is left too late, progressive neurodegeneration in PD can mean patients’ capacity to respond to these treatments may be significantly reduced.3,22
In patients with PD, consider non-oral therapies before severe motor symptoms and loss of functioning worsen.4
Based on a peer-reviewed opinion article that aimed to support the social and economic benefits of optimised treatment for patients with PD
Early introduction of non-oral therapies may allow patients with PD to have better control of motor symptoms and an impact on quality of life, which may allow patients to live at home or stay at work for longer23
Hospital Episode Statistics (HES) data (2013–2018)24*
Patients with complex or advanced PD treated with non-oral therapies had fewer emergency hospital admissions and hip fractures compared to those on other treatment24*†‡
*Hospital Episode Statistics (HES) is a database of administrative healthcare data maintained by NHS digital. This applies to England only. †Means are total admissions over 5 years divided by no. of patients. ‡Any diagnosis of fracture of femur (ICD-10 Code S72).24
HES data for complex/advanced PD patients24
Parkinson’s UK estimated the prevalence of PD in England at 114,560 in 2015*†24
5-2-1 open dialogue resource
Get support for practical and early non-oral therapy discussions with tips on how to have an open conversation with patients and their loved ones
Discover how the 5-2-1 criteria could help you assess whether patients are ready for non-oral therapies
Stay connected
Keep up to date with future resources, support, and guidance to help you manage your patients with PD by filling out your details below and joining the mailing list.
Please only fill out your details if you are a UK registered healthcare professional.
1. Duodopa (levodopa/carbidopa intestinal gel) Summary of Product Characteristics. Available at: www.medicines.org.uk. Accessed: December 2022.
2. Antonini A, et al. Curr Med Res Opin. 2018;34:2063–73.
3. Mills J, Martin A. Br J Neurosci Nurs. 2015;11(2):92–7.
4. Worth PF. Pract Neurol. 2013;13(3):140–52.
5. NICE. Parkinson’s disease in adults. Available at: www.nice.org.uk/guidance/ng71. Accessed December 2022.
6. Parkinson’s UK. 2019 Parkinson’s audit: Summary report. Available from: https://www.parkinsons.org.uk/professionals/
uk-parkinsons-audit-transforming-care. Accessed December 2022.
7. AbbVie. Data on ]le, HPA data for DAT patients, UK-DUOD-220019.
8. Parkinson’s UK. Reporting on Parkinson’s: Information for journalists. Available at: https://www.parkinsons.org.uk/
about-us/reporting-parkinsons-information-journalists. Accessed December 2022.
9. Nyholm D. Parkinsonism Relat Disord. 2007;13 Suppl:S13–7.
10. Olanow CW, et al. Nat Clin Pract Neurol. 2006;2(7):382–92.
11. Varanese S, et al. Parkinsons Dis. 2010;2010:480260.
12. Fleisher JE, Stern MB. Curr Neurol Neurosci Rep. 2013;13(10):382.
13. Grosset KA, et al. Mov Disord. 2005;20(11):1502–7.
14. Pahwa R, et al. Parkinsonism Relat Disord. 2019;60:118–25.
15. Odin P, et al. Parkinsonism Relat Disord. 2015;21:1133–44.
16. Kerr C, et al. Qual Life Res. 2016;25(6):1505–15.
17. Haahr A, et al. J Adv Nurs. 2011;67(2):408–17.
18. Antonini A, et al. Neurol Ther. 2022;11(1):303–18.
19. Mantri S, et al. J Patient Cent Res Rev. 2021;8(3):232–8.
20. Rastgardani T, et al. Mov Disord Clin Pract. 2018;5(5):461–70.
21. Stocchi F, et al. Parkinsonism Relat Disord. 2014;20(2):204–11.
22. Thanvi BR, Lo TCN. Postgrad Med J. 2004;80(946):452–8.
23. Lökk J, et al. Eur Neurol Rev. 2012;7(2):113–7.
24. AbbVie Ltd. Data on File. REF-37728.
25. Smolensky L, et al. Sci Data. 2020;7(1):67.
Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk.
Adverse events should also be reported to AbbVie on [email protected]
UK-DUOD-220207. Date of preparation: December 2022